Cargando…

Identification of biomarkers in pazopanib treated patients with renal cell carcinoma

Detalles Bibliográficos
Autores principales:	Pick, Amy M., Cochrane, Zara Risoldi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2013
Materias:	Research Highlight
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4708218/ https://www.ncbi.nlm.nih.gov/pubmed/26816734 http://dx.doi.org/10.3978/j.issn.2223-4683.2012.08.02

Ejemplares similares

One year survivor of metastatic renal cell carcinoma treated with pazopanib
por: Inn, Fam Xeng, et al.
Publicado: (2017)

Pazopanib for the Treatment of Patients with Advanced Renal Cell Carcinoma
por: Lang, Joshua M., et al.
Publicado: (2010)

Metformin Use and the Outcome of Metastatic Renal Cell Carcinoma Treated with Sunitinib or Pazopanib
por: Fiala, Ondřej, et al.
Publicado: (2021)

IL8 polymorphisms and overall survival in pazopanib- or sunitinib-treated patients with renal cell carcinoma
por: Xu, C-F, et al.
Publicado: (2015)

Pazopanib in Patients with Clear-Cell Renal Cell Carcinoma: Seeking the Right Patient
por: Porta, Camillo, et al.
Publicado: (2017)

Sequential Treatment with Pazopanib and Everolimus in Metastatic Renal Cell Carcinoma
por: Rossetti, Sabrina, et al.
Publicado: (2017)

Induction of trismus by sunitinib and pazopanib in metastatic renal cell carcinoma
por: Iyer, Ridhima, et al.
Publicado: (2017)

Critical appraisal of pazopanib as treatment for patients with advanced metastatic renal cell carcinoma
por: Bukowski, Ronald M
Publicado: (2011)

Dental pulp stem cells for treating neurodegenerative diseases
por: Shamir, Christopher, et al.
Publicado: (2015)

Neoadjuvant pazopanib and molecular analysis of tissue response in renal cell carcinoma
por: Wood, Christopher G., et al.
Publicado: (2020)

Pharmacotherapy Options in Advanced Renal Cell Carcinoma: What Role for Pazopanib?
por: Harrison, Michael R.
Publicado: (2011)

New advancements and developments in treatment of renal cell carcinoma: focus on pazopanib
por: Cowey, C Lance, et al.
Publicado: (2010)

Long-Term Control of Metastatic Renal Cell Carcinoma Using Pazopanib
por: Kawahara, Takashi, et al.
Publicado: (2019)

The complexity of sunitinib dosing in renal cell cancer patients
por: Desar, Ingrid M.E., et al.
Publicado: (2012)

Pazopanib: Evidence review and clinical practice in the management of advanced renal cell carcinoma
por: Méndez-Vidal, María José, et al.
Publicado: (2018)

Tyrosine Kinase Inhibitors in the Treatment of Advanced Renal Cell Carcinoma: Focus on Pazopanib
por: Vasudev, Naveen S., et al.
Publicado: (2011)

What a Clinician Should Know About a Renal Replacement Membrane?
por: Honore, Patrick M., et al.
Publicado: (2018)

Clinical Outcome of Third-Line Pazopanib in a Patient with Metastatic Renal Cell Carcinoma
por: Roberto, Michela, et al.
Publicado: (2015)

Pazopanib together with 6–8 cycles of sintilimab followed by single use of pazopanib in the second-line treatment of advanced renal cell carcinoma
por: Lu, Xiaolin, et al.
Publicado: (2021)

Antibiotic adjuvants: identification and clinical use
por: Bernal, Patricia, et al.
Publicado: (2013)

Successful re-administration of Pazopanib in a patient with metastatic renal cell carcinoma and a history of Pazopanib-induced nephrotic syndrome: a case report
por: Jeon, So-Yeon, et al.
Publicado: (2019)

Explorative probes and biomarkers, chronic Salmonella infections and future vaccines
por: Michán, Carmen, et al.
Publicado: (2012)

Plasma pTau181 as a biomarker for Alzheimer's disease
por: Meng, Jie, et al.
Publicado: (2020)

Rationale for targeted therapies and potential role of pazopanib in advanced renal cell carcinoma
por: Clark, Peter E
Publicado: (2010)

Rapid hair depigmentation in patient treated with pazopanib
por: Šeparović, Robert, et al.
Publicado: (2018)

Cost-effectiveness of pazopanib versus sunitinib for metastatic renal cell carcinoma in the United Kingdom
por: Amdahl, Jordan, et al.
Publicado: (2017)

Saliva biomarkers in neurological disorders: A “spitting image” of brain health?
por: Walton, Emma Louise
Publicado: (2018)

Tyrosine Kinase Inhibitor Pazopanib Inhibits Platelet Procoagulant Activity in Renal Cell Carcinoma Patients
por: Tullemans, Bibian M. E., et al.
Publicado: (2018)

Durable Response to Pazopanib in a Patient with Fumarate Hydratase-Mutant Tubulocystic Renal Cell Carcinoma
por: Othman, Anjum, et al.
Publicado: (2023)

Relationships between pazopanib exposure and clinical safety and efficacy in patients with advanced renal cell carcinoma
por: Suttle, A B, et al.
Publicado: (2014)

Relationships between pazopanib exposure and clinical safety and efficacy in patients with advanced renal cell carcinoma
por: Suttle, A B, et al.
Publicado: (2014)

Real-World Treatment Patterns and Costs for Patients with Renal Cell Carcinoma Initiating Treatment with Sunitinib and Pazopanib
por: MacLean, Elizabeth, et al.
Publicado: (2016)

A Case of Cardiac Tamponade in a Patient with Metastatic Renal Cell Carcinoma on Pazopanib Treatment
por: Sarathy, Vinu, et al.
Publicado: (2020)

COMPARZ Post Hoc Analysis: Characterizing Pazopanib Responders With Advanced Renal Cell Carcinoma
por: Sternberg, Cora N., et al.
Publicado: (2019)

SMIP-30, a potent and selective PPM1A inhibitor with potential to treat tuberculosis
por: Xu, Shujing, et al.
Publicado: (2022)

Real World Overall Survival of Patients With Metastatic Renal Cell Carcinoma Treated With Only Available Sunitinib and Pazopanib in First-Line Setting
por: Nikic, Predrag, et al.
Publicado: (2022)

Budget impact analysis of first-line treatment with pazopanib for advanced renal cell carcinoma in Spain
por: Villa, Guillermo, et al.
Publicado: (2013)

Artificial intelligence-assisted niacin skin flush screening in early psychosis identification and prediction
por: Chen, Tao, et al.
Publicado: (2022)

Persistence and Compliance with Pazopanib in Patients with Advanced Renal Cell Carcinoma Within a U.S. Administrative Claims Database
por: Hackshaw, Michelle D., et al.
Publicado: (2014)

Does Dose Modification Affect Efficacy of First-Line Pazopanib in Metastatic Renal Cell Carcinoma?
por: Grassi, Paolo, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_pchs95m1asqjrf82dcp2r3jt89